-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Bicycle Therapeutics, Lowers Price Target to $32

Benzinga·05/02/2025 18:36:53
Listen to the news
RBC Capital analyst Gregory Renza maintains Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and lowers the price target from $35 to $32.